Trial Profile
A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 02 Dec 2021 Results evaluating HBV reactivation during ledipasvir/sofosbuvir treatment and 108-week follow-up published in the Clinical Infectious Diseases
- 01 Oct 2020 Results integrating analysis of three clinical trials (NCT02202980, NCT02613871 and NCT02738333) published in the Hepatology Research
- 21 Nov 2018 Status changed from active, no longer recruiting to completed.